
    
      This short-term study will assess changes in hepatic steatosis over a 13-week treatment
      period in a patient population with higher risk for development of Nonalcoholic fatty liver
      disease (NAFLD) and Nonalcoholic steatohepatitis (NASH), obese type 2 diabetes mellitus
      (T2DM) with elevated HbA1c.
    
  